Tumor-associated macrophages and CD3-ζ expression of tumor-infiltrating lymphocytes in human esophageal squamous-cell carcinoma

Diseases of the Esophagus

Volumn 20, Issue 2, 2007, Pages 107-116

  Guo, S J ^a   Lin, D M ^b   Li, J ^a   Liu, R Z ^a   Zhou, C X ^a   Wang, D M ^a   Ma, W B ^a   Zhang, Y H ^a   Zhang, Shuren R ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Carcinoma; CD3 ; Esophagus; Macrophages; Prognosis

Indexed keywords

CD3 ANTIBODY; CD3 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL DENSITY; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CARCINOMA, SQUAMOUS CELL; EPITHELIUM; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS;

EID: 34147128107     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00655.x     Document Type: Article

References (45)

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics. CA Cancer J Clin 1994; 44: 7-26.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
3. Souza RF. Molecular and biologic basis of upper gastrointestinal malignancy-esophageal carcinoma. Surg Oncol Clin North Am 2002; 11: 257-72.
4. Stoner GD, Gupta A. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 2001; 22: 1737-46.
5. Mantovani A. Tumor-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines. Lab Invest 1994; 71: 5-16.
6. Mantovani A, Ming WJ, Balotta C, Abdeljalil B, Bottazzi B. Origin and regulation of tumor-associated macrophages: The role of tumor-derived chemotactic factors. Biochem Biophys Acta 1986; 865: 59-97.
7. Wu S, Boyer CM, Whitaker RS, Berchuch A, Weinberg JB, Bast RCJ. Tumor necrosis factor-alpha as an antocrine and paracrine growth factor for ovarian cancer: Monokine induction of tumor cell proliferation and tumor necrosis factor-alpha expression. Cancer Res 1993; 53: 1939-44.
8. Polverini PJ. Role of the macrophage in angiogenesis-dependent disease. EXS 1997; 79: 11-28.
9. Chen YX, Wang DB. Preliminary study on the immune function of esophageal cancer patients, patients with severe hyperplastic of esophageal epithelium and normal control. Compilation of Scientific Articles from 1958 to 1978 for 20 Years Anniversary (published by Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences). 1978; page: 188-90.
10. Germain RN, Stefanova I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 1999; 17: 467-522.
11. Samelson LE. Signal transduction mediated by the T cell antigen receptor: The role of adapter proteins. Annu Rev Immunol 2002; 20: 371-94.
12. Koretzky GA, Myung PS. Positive and negative regulation of T-cell activation by adaptor proteins. Nat Rev Immunol 2001; 1: 95-107.
13. Kersh EN, Shaw AS, Allen PM. Fidelity of T cell activation through multistep T cell receptor ζ phosphorylation. Science 1998; 281: 572-5.
14. Tartour E, Latour S, Mathiot C et al. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: Relationship with TIL phenotype and function. Int J Cancer 1995; 63: 205-12.
15. Zea AH, Curti BD, Longo DL et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995; 1: 1327-35.
16. Matsuda M, Petersson M, Lenkei R et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease. Int J Cancer 1995; 61: 765-72.
17. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 1996; 2: 161-73.
18. Rossi E, Matutes E, Morilla R, Owusu-Ankomah K, Heffernan AM, Catovsky D. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996; 10: 494-7.
19. Kono K, Ressing ME, Brandt RM et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996; 2: 1825-8.
20. Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ. T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 1997; 40: 113-19.
21. Bukowski R M, Rayman P, Uzzo R et al. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: Clinical relevance and effects of cytokine therapy. Clin Cancer Res 1998; 4: 2337-47.
22. Kurt RA, Urba WJ, Smith JW, Schoof DD. Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int J Cancer 1998; 78: 16-20.
23. Kuss I, Saito T, Johnson JT, Whiteside TL. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999; 5: 329-34.
24. Kim CW, Choi SH, Chung EJ et al. Alteration of signal-transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients. Pathobiology 1999; 67: 123-8.
25. Takahashi A, Kono K, Amemiya H, Iizuka H, Fujii H, Matsumoto Y. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. Clin Cancer Res 2001; 7: 74-80.
26. Kuss I, Rabinowich H, Gooding W, Edwards R, Whiteside TL. Expression of zeta in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biother Radiopharm 2002; 17: 631-40.
27. Han Y, Li C L, Lu L et al. Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance. Zhong Hua Zhong Liu Za Zhi 2004; 26: 158-60.
28. Kono K, Salazar-Onfray F, Petersson M et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing ζ molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytoxicity. Eur J Immunol 1996; 26: 1308-13.
29. Taheri F, Ochoa JB, Faghiri Z et al. L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurket cells. Clin Cancer Res 2001; 7: 958s-65s.
30. Rodriguez PC, Zea AH, Desalvo J et al. L-Arginine consumption by macrophages modulates the expression of CD3ζ chain in T lymphocytes. J Immunol 2003; 17: 1232-9.
31. Rodriguez PC, Quiceno DG, Zabaleta J et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64: 5839-49.
32. Mazzoni A, Bronte V, Visintin A et al. Myeloid suppressor lines inhibit T cell response by an NO-dependent mechanism. J Immunol 2002; 168: 689-95.
33. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000; 60: 5857-61.
34. Ishigami S, Natsugoe S, Tokuda K et al. Tumor-associated macrophages (TAM) infiltration in gastric cancer. Anticancer Res 2003; 23: 4079-84.
35. Ishigami S, Natsugoe S, Tokuda K et al. CD3-ζ expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 2002; 94: 1437-42.
36. Torsten ER, Roger D, Wanger EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998; 58: 5344-7.
37. Bingle L, Brown NJ, Lewis CE. The role of tomor-associated macrophages in tumor progression: Implications for new anticancer therapies. J Pathol 2002; 196: 254-65.
38. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56: 4625-9.
39. Fiumara A, Belfiore A, Russo G et al. In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer. J Clin Endocrinol Metab 1997; 82: 1615-20.
40. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer. relation to clinicopathological variables and survival. Int J Oncol 2000; 17: 445-51.
41. Ma Y, Xian M, Li J, Kawabata T, Okada S. Interrelations of clinicopathological variables, local immune response and prognosis in esophageal squamous cell carcinoma. APMIS 1999; 107: 514-22.
42. Ohta M, Kitadai Y, Tanaka S et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002; 102: 220-4.
43. Ohashi Y, Ishibashi S, Suzuki T et al. Significance of tumor associated tissue eosinophilia and other inflammatory cell infiltrate in early esophageal squamous cell carcinoma. Anticancer Res 2000; 20: 3025-30.
44. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2004; 99: 1667-74.
45. Whiteside TL. Down-regulation of ζ-chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol Immunother 2004; 53: 865-78.